[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355950-105":59,"doc-detail-355950-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","bone-related-adverse-events-of-hormonal-therapy-a-pharmacovigilance-study-based-on-the-food-drug-administration-adverse-event-reporting-system","Bone-related adverse events of hormonal therapy - A pharmacovigilance study based on the Food & Drug Administration Adverse Event Reporting System","","Study evaluating hormonal therapies’ association with bone adverse events using the FDA Adverse Event Reporting System (FAERS) and transcriptomic datasets to clarify potential molecular mechanisms. FAERS disproportionality analysis assessed adverse events across five hormonal therapy drug categories, while Gene Expression Omnibus analyses (GSE147271, GSE20181) identified bone-related pathways and differentially expressed genes. Fifty-seven significant bone signals, including 22 important medical events, were found, especially fractures, osteoporosis, and bone metastases. Estrogen-related events emerged after 6 months; androgen-related events earlier. Key genes (FOS, JUN, COL1A1, IGF1) implicated JAK signaling.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/bone-related-adverse-events-of-hormonal-therapy-a-pharmacovigilance-study-based-on-the-food-drug-administration-adverse-event-reporting-system/355950/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/bone-related-adverse-events-of-hormonal-therapy-a-pharmacovigilance-study-based-on-the-food-drug-administration-adverse-event-reporting-system/355950.png","ImageObject",300,407,{"name":92,"@type":93},"Ben ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data sources were used to study bone-related adverse events from hormonal therapy?","Question",{"text":112,"@type":113},"The study analyzed FAERS reports for hormonal-therapy–related adverse events and used transcriptomic data from Gene Expression Omnibus datasets (GSE147271 and GSE20181) to investigate bone-related pathways and genes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which bone adverse events were most commonly identified in the results?",{"text":117,"@type":113},"The analysis identified 57 significant bone-related signals, most commonly fractures at various sites, osteoporosis, and bone metastases.",{"name":119,"@type":110,"acceptedAnswer":120},"How did event timing differ between estrogen- and androgen-related adverse events?",{"text":121,"@type":113},"Estrogen-related adverse events typically occurred after about 6 months, whereas androgen-related events appeared earlier.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355950,1790920415,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Bone-related adverse events of hormonal therapy: A pharmacovigilance study based on the Food & Drug Administration Adverse Event Reporting System  \nYantian Wang 1,2,\\#, Anqi Li2,\\#, Jiafu Wang3,\\# and Min Xie 1,4   \nJournal of International Medical Research 2026, Vol. 54(7) 1–14 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/03000605261463660](DOI: 10.1177/03000605261463660)[ ](DOI: 10.1177/03000605261463660)[journals.sagepub.com/home/imr](journals.sagepub.com/home/imr)  \nAbstract  \nObjective: This study aimed to evaluate the association between hormonal therapies and bone adverse events using the Food & Drug Administration Adverse Event Reporting System (FAERS) and to explore possible molecular mechanisms. Methods: FAERS data were analyzed for adverse events related to ﬁve hormonal therapy drug categories, and disproportionality analysis was used to identify signiﬁcant adverse events. Transcriptomic data from Gene Expression Omnibus datasets (GSE147271 and GSE20181) were analyzed to identify bone-related pathways and differentially expressed genes. Results: Overall, 57 signiﬁcant bone-related signals, including 22 Important Medical Events, were identiﬁed, most commonly fractures at various sites, osteoporosis, and bone metastases associated with estrogen receptor-targeted drugs and aromatase inhibitors. Estrogen-related adverse events typically occurred after 6 months, whereas androgen-related events appeared earlier. Transcriptomic analysis identiﬁed FOS, JUN, COL1A1, and IGF1 as key genes, implicating the Janus kinase signaling pathway in bone injury.  \nConclusion: This study demonstrates a strong association between hormonal therapy drugs and bone-related adverse events, particularly fractures and bone cancers. It emphasizes the importance of monitoring bone health and suggests the Janus kinase signaling pathway as a potential therapeutic target for mitigating bone-related adverse events.  \nKeywords  \nFood & Drug Administration Adverse Event Reporting System database, hormonal therapy, bone-related adverse event, estrogen receptor-targeted drug, aromatase inhibitor, androgen receptor antagonist  \nReceived: 20 May 2026; revised: 20 May 2026; accepted: 9 June 2026  \nIntroduction  \nHormonal therapy targets hormone pathways to treat conditions driven by hormonal imbalances, including thyroid dysfunction, polycystic ovary syndrome (PCOS), and menopausal symptoms, offering signiﬁcant potential in personalized  \n1 Department of Operating Room Nursing, West China Second University Hospital, Sichuan University, China  \n2Key Laboratory of BioResource and Eco-Environment of Ministry of Education, College of Life Science, Sichuan University, China 3Pathology Department, Shenzhen Maternity & Child Healthcare Hospital, China  \n4Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, China  \n\\#  \nThese authors contributed equally to this work.  \nCorresponding author:  \nMin Xie, Department of Operating Room Nursing, West China Second University Hospital, Sichuan University, Chengdu, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, Sichuan, China.  \nEmail: [llan7936@163.com](llan7936@163.com)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution  \nNonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as speciﬁed on the SAGE and Open Access page ([https://us](https://us). [sagepub.com/en-us/nam/open-access-at-sage](sagepub.com/en-us/nam/open-access-at-sage)).  \nmedicine.1–3 In oncology, hormo","cbCaidyDo8hE3YAt","https://ap.wps.com/l/cbCaidyDo8hE3YAt","pdf",3079764,14,"English","# Abstract\n## Objective and Methods\n## Results\n## Conclusion\n# Keywords\n# Introduction\n## Rationale for Hormonal Therapy in Cancer\n## Drug Classes Targeting Estrogen and Androgen Pathways","[{\"question\":\"What data sources were used to study bone-related adverse events from hormonal therapy?\",\"answer\":\"The study analyzed FAERS reports for hormonal-therapy–related adverse events and used transcriptomic data from Gene Expression Omnibus datasets (GSE147271 and GSE20181) to investigate bone-related pathways and genes.\"},{\"question\":\"Which bone adverse events were most commonly identified in the results?\",\"answer\":\"The analysis identified 57 significant bone-related signals, most commonly fractures at various sites, osteoporosis, and bone metastases.\"},{\"question\":\"How did event timing differ between estrogen- and androgen-related adverse events?\",\"answer\":\"Estrogen-related adverse events typically occurred after about 6 months, whereas androgen-related events appeared earlier.\"}]","Bone-related adverse events of hormonal therapy - A pharmacovigilance study based on the Food & Drug Administration Adverse Event Reporting System | PDF",1790121928,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1367b9f1c21d176bbc1f242485373c2.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5515166026cd3fc74461f53e2deb3783.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9e2e7861ef083f0f764e1f2198fcaa5.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74c6417e388b2bf197211ad5d946299f.webp",980,1306]